{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T17:51:42Z","timestamp":1766771502106,"version":"3.48.0"},"reference-count":0,"publisher":"Romanian Society of Gastroenterology and Hepatology","issue":"4","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JGLD"],"abstract":"<jats:p>Background and Aims: Until recently, the only available treatment option for hepatitis D virus (HDV) was the off-label use of interferon, which is associated with limited efficacy and considerable side effects. The approval of the first HDV-direct antiviral, bulevirtide (BLV), has introduced a targeted therapeutic option for patients with chronic hepatitis delta. We assessed the clinical efficacy of BLV in our HDV patients.\nMethods: We conducted a retrospective analysis of all patients diagnosed with HDV infection in our department over the past 10 years. For statistical analysis, we performed multivariate analysis of variance, MANOVA.\nResults: 26 patients tested positive for HDV antibodies (17 developed chronic hepatitis delta). Eleven patients received BVD. At treatment initiation, liver cirrhosis was present in three patients in the bulevirtide group (MELD-Na: 9\u201310; Child-Pugh: 5\u20137) and in three patients in the no bulevirtide group (MELD-Na: 13\u201318; Child-Pugh: 5\u20138). Over 12 months of follow-up, bulevirtide recipients showed reductions in alanine aminotransferase (ALT; mean baseline 88 U\/L vs 59 U\/L; controls 230 U\/L vs 206 U\/L; MANOVA between-subject effect: p&lt;0.05), aspartate aminotransferase (AST; 68 U\/L vs 56 U\/L; controls 208 U\/L vs 151 U\/L; p&lt;0.05), bilirubin (0.74 mg\/dL vs 0.65 mg\/dL; controls 1.48 mg\/dL vs 1.17 mg\/dL; p&lt;0.005), HDV-RNA (1,323,182 copies\/mL vs 36,975 copies\/mL; controls 416,825 copies\/mL vs 17,914,733 copies\/mL; p&lt;0.05) a statistically significant time-by-group interaction was found for both Child-Pugh scores (p&lt;0.0001) and MELD-Na scores (p&lt;0.05), indicating improved liver function over time in the BLV group compared to controls. No progression of liver fibrosis was observed.\nConclusions: Bulevirtide is a safe and effective treatment for chronic hepatitis delta in a real-world clinical setting. These findings support its role as a sustainable therapeutic option for patients with HDV infection.<\/jats:p>","DOI":"10.15403\/jgld-6501","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T17:46:57Z","timestamp":1766771217000},"page":"467-473","source":"Crossref","is-referenced-by-count":0,"title":["A Decade of Bulevirtide Use in Chronic Hepatitis Delta: Real-World Clinical Results"],"prefix":"10.15403","volume":"34","author":[{"given":"Sophia","family":"Rusch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"St\u00f6ckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6121","published-online":{"date-parts":[[2025,12,26]]},"container-title":["Journal of Gastrointestinal and Liver Diseases"],"original-title":[],"link":[{"URL":"https:\/\/jgld.ro\/jgld\/index.php\/jgld\/article\/download\/6501\/2256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jgld.ro\/jgld\/index.php\/jgld\/article\/download\/6501\/2256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T17:46:58Z","timestamp":1766771218000},"score":1,"resource":{"primary":{"URL":"https:\/\/jgld.ro\/jgld\/index.php\/jgld\/article\/view\/6501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,26]]}},"URL":"https:\/\/doi.org\/10.15403\/jgld-6501","relation":{},"ISSN":["1842-1121","1841-8724"],"issn-type":[{"value":"1842-1121","type":"electronic"},{"value":"1841-8724","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,26]]}}}